AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer
出版年份 2022 全文链接
标题
AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer
作者
关键词
-
出版物
BMC CANCER
Volume 22, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-04-24
DOI
10.1186/s12885-022-09511-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- 30 years of HER3: From basic biology to therapeutic interventions
- (2021) Heidi M. Haikala et al. CLINICAL CANCER RESEARCH
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- AXL mediates cetuximab and radiation resistance through tyrosine 821 and the c-ABL kinase pathway in head and neck cancer
- (2020) Nellie K McDaniel et al. CLINICAL CANCER RESEARCH
- Inhibition of tumor cell growth and cancer stem cell expansion by a bispecific antibody targeting EGFR and HER3
- (2020) Alexander Rau et al. MOLECULAR CANCER THERAPEUTICS
- Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
- (2020) David G. Pfister et al. Journal of the National Comprehensive Cancer Network
- The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells
- (2020) Wen-Qi Cai et al. Frontiers in Oncology
- AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer
- (2020) Claudia Cardone et al. EUROPEAN JOURNAL OF CANCER
- AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
- (2019) Hirokazu Taniguchi et al. Nature Communications
- Development of Effective Therapeutics Targeting HER3 for Cancer Treatment
- (2019) Xiaolong Liu et al. BIOLOGICAL PROCEDURES ONLINE
- Neuregulin Signaling is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma.
- (2019) Marta Baro et al. MOLECULAR CANCER THERAPEUTICS
- AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications
- (2019) Chenjing Zhu et al. Molecular Cancer
- Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study
- (2019) Martin D. Forster et al. EUROPEAN JOURNAL OF CANCER
- Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer
- (2018) Charline Ogier et al. CANCER LETTERS
- BET inhibition overcomes receptor tyrosine kinase-mediated cetuximab resistance in HNSCC
- (2018) Brandon Leonard et al. CANCER RESEARCH
- Response to ERBB3-Directed Targeted Therapy in NRG1 -Rearranged Cancers
- (2018) Alexander Drilon et al. Cancer Discovery
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- MERTK mediates intrinsic and adaptive resistance to AXL-targeting agents
- (2018) Nellie K McDaniel et al. MOLECULAR CANCER THERAPEUTICS
- Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non–Small Cell Lung Cancer Cells
- (2018) Kei Namba et al. MOLECULAR CANCER RESEARCH
- Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC
- (2017) Adam D. Swick et al. MOLECULAR CANCER THERAPEUTICS
- ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC
- (2017) Diego Alvarado et al. PLoS One
- Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer
- (2016) Shi Hu et al. CANCER LETTERS
- HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models
- (2016) Dongsheng Wang et al. CLINICAL CANCER RESEARCH
- Human epidermal growth factor receptor 3 in head and neck squamous cell carcinomas
- (2016) Bénédicte Rysman et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab
- (2016) M. Iida et al. MOLECULAR CANCER THERAPEUTICS
- Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)
- (2016) Jérôme Fayette et al. Frontiers in Oncology
- Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models
- (2015) D. M. Francis et al. CLINICAL CANCER RESEARCH
- Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies
- (2015) N. I. Pollock et al. CLINICAL CANCER RESEARCH
- AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma
- (2015) T. M. Brand et al. CLINICAL CANCER RESEARCH
- Targeting HER (ERBB) signaling in head and neck cancer: An essential update
- (2015) Jun Zhang et al. MOLECULAR ASPECTS OF MEDICINE
- Inhibition of ErbB3 by a monoclonal antibody that locks the extracellular domain in an inactive configuration
- (2015) Sangwon Lee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells
- (2015) Hisato Kawakami et al. Oncotarget
- AXL Mediates Resistance to Cetuximab Therapy
- (2014) T. M. Brand et al. CANCER RESEARCH
- Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models
- (2014) K. Meetze et al. CLINICAL CANCER RESEARCH
- Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy
- (2014) Mari Iida et al. Molecular Cancer
- Axl Kinase as a Key Target for Oncology: Focus on Small Molecule Inhibitors
- (2014) C. Feneyrolles et al. MOLECULAR CANCER THERAPEUTICS
- Activation of HER3 Interferes with Antitumor Effects of Axl Receptor Tyrosine Kinase Inhibitors: Suggestion of Combination Therapy
- (2014) Robert Torka et al. NEOPLASIA
- MET and AXL Inhibitor NPS-1034 Exerts Efficacy against Lung Cancer Cells Resistant to EGFR Kinase Inhibitors Because of MET or AXL Activation
- (2013) J. K. Rho et al. CANCER RESEARCH
- Axl Mediates Acquired Resistance of Head and Neck Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Erlotinib
- (2013) Keith M. Giles et al. MOLECULAR CANCER THERAPEUTICS
- Blocking NRG1 and Other Ligand-Mediated Her4 Signaling Enhances the Magnitude and Duration of the Chemotherapeutic Response of Non-Small Cell Lung Cancer
- (2013) G. V. Hegde et al. Science Translational Medicine
- Dual Targeting of EGFR and HER3 with MEHD7945A Overcomes Acquired Resistance to EGFR Inhibitors and Radiation
- (2012) S. Huang et al. CANCER RESEARCH
- Development and Characterization of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma Tumorgrafts
- (2012) R. J. Kimple et al. CLINICAL CANCER RESEARCH
- An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
- (2012) L. A. Byers et al. CLINICAL CANCER RESEARCH
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
- (2012) Zhenfeng Zhang et al. NATURE GENETICS
- Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer
- (2012) R M A Linger et al. ONCOGENE
- Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma
- (2011) Mikiko Takikita et al. Journal of Translational Medicine
- Understanding resistance to EGFR inhibitors—impact on future treatment strategies
- (2010) Deric L. Wheeler et al. Nature Reviews Clinical Oncology
- An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies
- (2010) X Ye et al. ONCOGENE
- Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
- (2008) D L Wheeler et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now